Biogen (BIIB) to Post Earnings on Wednesday

Biogen (NASDAQ:BIIB) will likely be releasing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $3.02 per share and revenue of $2.4567 billion for the quarter. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the firm earned $3.02 earnings per share. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. On average, analysts expect Biogen to post $11 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Biogen Stock Performance

Biogen stock opened at $202.19 on Monday. Biogen has a 12-month low of $124.56 and a 12-month high of $219.72. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The company has a market capitalization of $29.85 billion, a price-to-earnings ratio of 21.69 and a beta of 0.16. The firm’s fifty day moving average price is $199.78 and its 200 day moving average price is $189.95.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BIIB. Boston Partners bought a new position in Biogen in the 4th quarter worth approximately $302,815,000. Orion Porfolio Solutions LLC raised its stake in Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after acquiring an additional 509,809 shares in the last quarter. Caisse de depot et placement du Quebec raised its stake in Biogen by 718.2% during the 3rd quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock valued at $79,741,000 after acquiring an additional 499,676 shares in the last quarter. AQR Capital Management LLC boosted its position in Biogen by 30.7% during the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock worth $248,809,000 after acquiring an additional 418,776 shares during the period. Finally, HRT Financial LP boosted its position in Biogen by 8,542.9% during the 4th quarter. HRT Financial LP now owns 384,265 shares of the biotechnology company’s stock worth $67,626,000 after acquiring an additional 379,819 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Argus upgraded Biogen to a “hold” rating in a research note on Thursday, April 9th. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Citigroup increased their price target on Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Rothschild & Co Redburn raised their price target on shares of Biogen from $180.00 to $190.00 in a research report on Thursday, April 30th. Finally, Guggenheim lifted their price target on Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $220.57.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.